ArticleAmerican journal of hematology2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
Article in American journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Racial, ethnic, sex, and age representation in clinical trials of radiopharmaceutical tumor therapy: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.British journal of haematology · 2014Trial
- Engineering bioactive mineralized tumor cells for tumor immunotherapy.Frontiers in bioengineering and biotechnology · 2025Article
- [Non-targeted Metabolomics-based Exploration of Radiation-induced Metabolic Alterations in Mouse Lung Epithelial Cells].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide-coated nanoparticles.Blood advances · 2022Article
- Review
- Review
- Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer.Annals of surgical oncology · 2021Article
- Therapeutic vaccines for aggressive B-cell lymphoma.Leukemia & lymphoma · 2020Article
- Synergistic Toll-like Receptor 3/9 Signaling Affects Properties and Impairs Glioma-Promoting Activity of Microglia.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020Article
- Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis.Cell death & disease · 2018Article
- Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo.Pharmaceuticals (Basel, Switzerland) · 2018Article
- In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.Cancer immunology, immunotherapy : CII · 2017Article
- Building better monoclonal antibody-based therapeutics.Nature reviews. Cancer · 2015Review
- Haematological malignancies: at the forefront of immunotherapeutic innovation.Nature reviews. Cancer · 2015Review
- MRI Contrast Agents for Pharmacological Research.Frontiers in pharmacology · 2015Article
- CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells.OncoTargets and therapy · 2015Article
- Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Vaccine · 2014Review
- Trial Watch: Radioimmunotherapy for oncological indications.Oncoimmunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Funding
Abstract
Radioimmunotherapy (RIT) for relapsed indolent non-Hodgkin lymphoma produces overall response rates (ORR) of 80% with mostly partial remissions. Synthetic CpG oligonucleotides change the phenotype of malignant B-cells, are immunostimulatory, and can produce responses when injected intratumorally and combined with conventional radiation. In this phase I trial, we tested systemic administration of both CpG and RIT. Eligible patients had biopsy-proven previously treated CD20+ B-cell NHL and met criteria for RIT. Patients received rituximab 250 mg/m(2) days 1,8, and 15; (111) In-ibritumomab tiuxetan days 1, 8; CpG 7909 days 6, 13, 20, 27; and 0.4 mCi/kg of (90) Y-ibritumomab tiuxetan day 15. The doses of CpG 7909 tested were 0.08, 0.16, 0.32 (six patients each) and 0.48 mg/kg (12 patients) IV over 2 hr without dose limiting toxicity. The ORR was 93% (28/30) with 63% (19/30) complete remission (CR); median progression free survival of 42.7 months (95% CI 18-NR); and median duration of response (DR) of 35 months (4.6-76+). Correlative studies demonstrated a decrease in IL10 and TNFα, and an increase in IL1β, in response to therapy. CpG 7909 at a dose of 0.48 mg/kg is safe with standard RIT and produces a high CR rate and long DR; these results warrant confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.